Want to see TSE:AVCR full AI Analyst Report?
AVCR Stock Chart & Stats
C$0.05
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.05
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.10
Previous CloseN/A
Volume151.36K
Average Volume (3M)51.37K
Market Cap
C$5.57M
Enterprise ValueC$6.88
Total Cash (Recent Filing)C$210.30K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding101,289,665
10 Day Avg. Volume29,762
30 Day Avg. Volume51,367
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)13.00
Price to Sales (P/S)9.49
P/FCF Ratio-5.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring POCT & HealthTab PlatformAvricore’s core model combines in-pharmacy point-of-care testing programs with a software platform (HealthTab) and recurring connectivity/reporting fees. That mix creates durable per-site revenue streams and customer stickiness when programs scale across pharmacy networks, supporting steady unit economics over months.
Very Low Financial LeverageHaving essentially no debt materially reduces near-term solvency risk and interest burden, giving management flexibility to fund operations or pivot via equity or partnerships. This lower leverage is a durable balance-sheet strength that cushions the business during cyclical downturns in test volumes.
Historically Solid Gross MarginsPrior to the recent downturn, the business delivered healthy gross margins (~44% in 2025), indicating the service/software mix can generate meaningful contribution per test. If volumes and pricing stabilize, these structural margins improve the firm’s path to operating leverage and long-term profitability.
Bears Say
Severe Recent Revenue DeclineA ~73% TTM decline erodes scale benefits and undermines unit economics: lower volumes reduce fixed-cost absorption and weaken recurring revenue visibility. Sustained top-line contraction increases financing needs and makes it harder to leverage prior margin strength into positive operating results over the next several months.
Negative And Worsening Operating Cash FlowThe shift from positive to negative operating cash flow and continued free cash burn increases dependence on external funding. Persistently negative cash generation constrains reinvestment, heightens dilution risk from future financings, and threatens continuity of programs unless operations are restructured or new capital sourced.
Eroded Equity Base And Dilution RiskA sharply reduced equity cushion limits the company’s ability to absorb further losses and increases the likelihood of dilutive capital raises. This weakens long-term shareholder resilience and can constrain strategic options such as investing in network expansion or absorbing temporary revenue shortfalls without issuing equity.
Avricore Health News
AVCR FAQ
What was Avricore Health Inc.’s price range in the past 12 months?
Avricore Health Inc. lowest stock price was C$0.04 and its highest was C$0.10 in the past 12 months.
What is Avricore Health Inc.’s market cap?
Avricore Health Inc.’s market cap is C$5.57M.
When is Avricore Health Inc.’s upcoming earnings report date?
Avricore Health Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 26 days.
How were Avricore Health Inc.’s earnings last quarter?
Currently, no data Available
Is Avricore Health Inc. overvalued?
According to Wall Street analysts Avricore Health Inc.’s price is currently Overvalued.
Does Avricore Health Inc. pay dividends?
Avricore Health Inc. does not currently pay dividends.
What is Avricore Health Inc.’s EPS estimate?
Avricore Health Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avricore Health Inc. have?
Avricore Health Inc. has 101,289,665 shares outstanding.
What happened to Avricore Health Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Avricore Health Inc.?
Currently, no hedge funds are holding shares in TSE:AVCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avricore Health Inc.
Avricore Health Inc. operates within Canada, specializing in health data management and point-of-care technological solutions. Their primary offering is HealthTab, a precise, laboratory-quality diagnostic testing system designed for use in pharmacies. This enterprise maintains key alliances with prominent organizations such as Shoppers Drug Marts and Abbott. Established in 1996 and headquartered in Vancouver, Canada, the company previously operated as Vanc Pharmaceuticals Inc., adopting its current name, Avricore Health Inc., in October 2018.
Technical Analysis
BioMark Diagnostics
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
―
PanGenomic Health, Inc. Class A
―